Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Common Equity (2021 - 2025)

Historic Common Equity for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $1.5 billion.

  • Rxo's Common Equity fell 440.45% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year decrease of 440.45%. This contributed to the annual value of $1.5 billion for FY2025, which is 440.45% down from last year.
  • Rxo's Common Equity amounted to $1.5 billion in Q4 2025, which was down 440.45% from $1.6 billion recorded in Q3 2025.
  • Rxo's Common Equity's 5-year high stood at $1.7 billion during Q3 2024, with a 5-year trough of $579.0 million in Q2 2024.
  • In the last 5 years, Rxo's Common Equity had a median value of $1.1 billion in 2021 and averaged $1.1 billion.
  • As far as peak fluctuations go, Rxo's Common Equity plummeted by 4842.66% in 2023, and later surged by 18000.0% in 2024.
  • Over the past 5 years, Rxo's Common Equity (Quarter) stood at $1.1 billion in 2021, then crashed by 45.14% to $587.0 million in 2022, then grew by 1.19% to $594.0 million in 2023, then skyrocketed by 171.38% to $1.6 billion in 2024, then fell by 4.4% to $1.5 billion in 2025.
  • Its Common Equity was $1.5 billion in Q4 2025, compared to $1.6 billion in Q3 2025 and $1.6 billion in Q2 2025.